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patients is predicted by health-related
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study (CAIR study)
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Abstract
Background: In patients with relapsing remitting multiple sclerosis (RRMS) the persistence of and adherence to
disease modifying drug (DMD) treatment is inadequate. To take individualised measures there is a need to identify
patients with a high risk of non-persistence or non-adherence. As patient-related factors have a major influence on
persistence and adherence, we investigated whether health-related quality of life (HRQoL) and self-efficacy could
predict persistence or adherence.
Methods: In a prospective web-based patient-centred study in 203 RRMS patients, starting treatment with glatiramer
acatete (GA) 20 mg subcutaneously daily, we measured physical and mental HRQoL (Multiple Sclerosis Quality of Life-
54 questionnaire), functional and control self-efficacy (Multiple Sclerosis Self-Efficacy Scale), the 12-month persistence
rate and, in persistent patients, the percentage of missed doses. HRQoL and self-efficacy were compared between
persistent and non-persistent patients, and between adherent and non-adherent patients. Logistic regression analysis
was used to assess whether persistence and adherence were explained by HRQoL and self-efficacy.
Results: Persistent patients had higher baseline physical (mean 58.1 [standard deviation, SD] 16.9) and mental HRQoL
(63.8 [16.8]) than non-persistent patients (49.5 [17.6]; 55.9 [20.4]) (P = 0.001; P = 0.003) with no differences between
adherent and non-adherent patients (P = 0.46; P = 0.54). Likewise, in persistent patients function (752 [156]) and control
self-efficacy (568 [178]) were higher than in non-persistent patients (689 [173]; 491 [192]) (P = 0.009; P = 0.004), but not
in adherent vs. non-adherent patients (P = 0.26; P = 0.82). Logistic regression modelling identified physical HRQoL and
control self-efficacy as factors that explained persistence. Based on predicted scores from the model, patients were
classified into quartiles and the percentage of non-persistent patients per quartile was calculated: non-persistence in
the highest quartile was 23.4 vs. 53.2% in the lowest quartile. Risk differentiation with respect to adherence was not
possible. Based on these findings we propose a practical work-up scheme to identify patients with a high risk of non-
persistence and to identify persistence-related factors.
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Conclusions: Findings suggest that pre-treatment physical HRQoL and control self-efficacy may identify RRMS patients
with a high risk of early discontinuation of injectable DMD treatment. Targeting of high-risk patients may enable the
efficient use of persistence-promoting measures.
Trial Registration: Nederlands Trial Register code: NTR2432.
Keywords: Multiple sclerosis, Relapsing remitting, Persistence, Adherence, Self-efficacy, Quality of life, Health-related
quality of life, Glatiramer acetate, Disease modifying treatment
Background
In patients with relapsing remitting multiple sclerosis
(RRMS) treatment with disease modifying drugs (DMDs)
is associated with a decrease in the frequency and sever-
ity of relapses [1], and a delayed conversion to secondary
progression [2]. In general, high DMD exposure is asso-
ciated with better clinical outcomes than low exposure
[3], and a continued use is thought to provide the great-
est long term benefit [4, 5]. However, medication for
chronic illness is only taken by 50 – 60% of the patients
as prescribed [6, 7]. Not taking medication as agreed
upon includes two different patient behaviours: missing
doses (non-adherence) and premature treatment discon-
tinuation (non-persistence) [7]. According to a World
Health Organization report five interacting dimensions
affect adherence and persistence: social and economic
factors, health care team and system-related factors,
condition-related factors, therapy-related factors and
patient-related factors. The latter factors represent the
resources, knowledge, attitudes, beliefs, expectations and
perceptions of the patient [7].
Health-related quality of life (HRQoL) is a multi-
dimensional concept that focuses on the impact health
status has on physical, mental, emotional and social di-
mensions of quality of life [8]. As an overall measure from
a patient’s perspective, HRQoL measures the disease im-
pact on health dimensions that can not be evaluated using
observer-based measures of physical disability [9–11]. In a
web-based survey among MS patients, higher HRQoL was
associated with better adherence to injectable DMD treat-
ment [12]. In a previous study of HRQoL in RRMS pa-
tients starting IM interferon-beta (INFb) we found that
patients who discontinued treatment within 24 months
had a lower physical or mental HRQoL at baseline than
those who continued treatment [13]. Theoretically, as an
overall patient-centerd concept, HRQoL may be thought
to comprehensively reflect patient-related factors affecting
persistence and adherence.
Self-efficacy is a psychological concept that refers to
the degree in which a person is confident to complete
tasks and reach goals in specific situations [14]. It is a
core component in social cognitive theory, in which
psychosocial functioning is determined by reciprocal in-
teractions between personal factors, behaviour and the
environment [15, 16]. In MS patients low self-efficacy
has been associated with less psychological adjustment
[17]. Two retrospective studies in the U.S.A. among pa-
tients treated with glatiramer acetate (GA) 20 mg sub-
cutaneously (sc) daily identified self-efficacy as predictor
of persistence, along with hope and perception of sup-
port, whereas in a prospective study in GA-treated pa-
tients self-efficacy was significantly related to 3-month
persistence [18–20].
Discontinuation of injectable DMD treatment in
RRMS patients mostly occurs in the first 12 months
[21–23]. After 6 months up to 27% may have discontin-
ued treatment [21], and after 14 months 43% of those
initiating therapy reported to be non-persistent [22].
From a practical point of view it could be useful to
neurologists and nurses to be able to identify those pa-
tients who are at high risk of early treatment discontinu-
ation or missing doses. Although various patient-related
factors have been found to be associated with non-
persistence or non-adherence, to our knowledge no
study provided an algorithm that quantifies the risk of
inadequate drug us in individual patients. In view of the
study reports and considerations mentioned above we
investigated in RRMS patients starting treatment with
GA 20 mg sc daily, whether persistence and adherence
were associated with HRQoL and self-efficacy, and
whether eventual associations could result in the devel-
opment of a predictive model for use in daily clinical
practice [24]. So, we analyzed self-efficacy and HRQol in
persistence vs. non-persistent, and in adherent vs. non-
adherent patients, and used logistic regression modelling
to predict persistence and adherence with HRQoL and
self-efficacy as independent variables.
Methods
Study design
The present analysis is part of the CAIR study, an
investigator-initiated, prospective, web-based, patient-
centred, observational study in The Netherlands. The
study’s name is an acronym from the principal analytical
method, main theme and study population: Correlative
analysis of Adherence In Relapsing remitting MS
(CAIR). The study duration was 12 months. Nederlands
Trial Register code: NTR2432. GA 20 mg sc daily was
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prescribed by neurologists as per regular care, dispensed
as a commercial drug by general pharmacies (Copaxone
®) and administered by the patient according to the in-
structions in the package leaflet.
The primary outcomes were the relationships between
adherence and persistence, and the numbers of care ses-
sions and the quantity of care per discipline. The
secondary outcomes were the relationships between ad-
herence and persistence, and patient characteristics,
socio-economic situation, health care, caregivers, disease
and treatment [24].
Patients were informed by neurologists, MS-nurses
and specialised nurses who teach patients to self-inject,
and via websites of patient organisations. Patients were
also advised to visit the study website. For further infor-
mation they could contact the study helpdesk by tele-
phone or e-mail, or the coordinating investigator (PJJ)
by e-mail. The recruitment period was from July 2009 to
July 2011 and comprised two phases. First, in 2009 15
MS-specialized neurological practices with an MS-nurse
were recruited as study sites. The practices were fairly
distributed over the country. Since July 2009 they in-
formed patients starting GA treatment of the possibility
to participate in the study. Objectives and overall re-
quirements were discussed with the patient. The study
information was preceded by the decision to start GA
treatment. When a patient decided to participate, the
neurologist or the MS-nurse notified the study help-
desk and participation was started. Second, since
February 2010 nurses who teach patients to self-inject
GA briefly informed patients about the study. Patients
interested in receiving further information were
handed a postage paid card addressed to the study
helpdesk. On receipt of the card the helpdesk con-
tacted the patient by phone and provided information.
Patients who, after being informed, were willing to
participate either signed the informed consent form at
their neurologist’s or MS-nurse’s office or, in case the
neurologist was not yet involved in the study, con-
firmed the text of the informed consent by clicking
on a specific page of the study website. In the latter
case the coordinating investigator contacted the neur-
ologist by phone or e-mail to introduce the study,
and provided the study protocol with informed con-
sent text. Within 2 weeks a second contact was estab-
lished and the neurologist informed the coordinating
investigator on his/her decision to participate or not.
If the neurologist participated he/she and the MS-
nurse were contacted by the helpdesk and the prac-
tice was activated as study site. A negative decision
by the neurologist did not interfere with the patient’s
participation, as the study was patient-centred and
the primary research question could be answered by
patient-derived data only.
The inclusion criteria were 1) indication for GA treat-
ment, 2) being relapse free and having stable symptoms
for at least 30 days, 3) willing and able to comply with
the protocol for the duration of the study, and 4) having
given written informed consent. The exclusion criteria
were 1) contra-indication to GA as defined in the
Summary of Product Characteristics text, 2) hypersen-
sitivity to GA or mannitol, 3) worsening of symptoms
suggestive of a relapse, 4) pregnancy or lactation, and
5) the time interval between the first GA injection
and baseline assessment was more than 4 weeks.
Technical aspects
The study was a modular application on the Curavista
e-health platform, built on an Oracle database with
JAVA-scripting, XML-applets and AJAX protocols. Data
processing was 256-bits encrypted with VPN-tunnelling.
The databases were physically and software secured in a
dedicated data centre in The Netherlands. The database
of the study was compliant with EU-regulations on data
storage and activation for medical purposes. There were
four separated databases: one with personal identifiers
(name, address, identification number), one with study
records (answers to the questions, identification num-
ber), one with the social security number, and one with
the key. Only after login the data were presented as a
whole on the screen (encrypted key).
Data acquisition
Data were acquired via a special study website. Patients
logged in with a code provided by the study help desk
and chose a username and password. Online they went
through web pages containing the electronic case record
forms (eCRFs). The questions and questionnaires related
to missed doses, discontinuation, adverse events, medi-
cation, relapses, self-efficacy, HRQoL and other adher-
ence- or persistence-related factors [24].
Patients were informed by email that an assessment
was due and that the corresponding forms had been
made available for completion. eCRFs were to be com-
pleted within one week. Completion could take as many
sessions as needed, as answers were saved automatically.
After confirmation by the patient the eCRF was auto-
matically sent to the study centre. Incomplete eCRFs
were returned. In case an eCRF was not completed
within one week, the help desk reminded the patient
by telephone.
Outcome measures
HRQoL was assessed via the Multiple Sclerosis Quality
of Life 54-Items (MSQoL-54) questionnaire [25]. The
MSQoL-54 is a psychometrically validated, MS-specific,
multi-dimensional inventory of patient-centered health
status, and consists of the Short Form 36-Item health
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survey as a generic core measure, supplemented with 18
questions on items relevant to persons with MS in the
areas of health distress, sexual function, satisfaction with
sexual function, overall quality of life, cognitive function,
energy, pain and social function [25]. The MSQoL-54
contains 52 items distributed into 12 scales, and two sin-
gle items. A physical and a mental dimension underlie
the MSQoL-54: the Physical and Mental domains [25].
Scores for each domain range from 0 to 100, where
higher values indicate better HRQoL.
Self-efficacy was assessed by means of the Multiple
Sclerosis Self-Efficacy Scale (MSSES). The MSSES is an
18-item, psychometrically validated, self-report question-
naire for the assessment of self-efficacy in patients with
MS [26]. The MSSES consists of two 9-item subscales of
Function and Control. Each item is scored on a Likert-
like scale form 10 (very uncertain) to 100 (very certain)
and addition of the respective item scores yields the
MSSES Function score and the MSSES Control score,
both ranging from 90 (minimum) to 900 (maximum).
The MSSES Function subscale measures confidence with
functional abilities, whereas the MSSES Control subscale
measures confidence with managing symptoms and cop-
ing with the demands of the illness [26]. The completion
of the HRQoL and self-efficacy questionnaires took
about 20 to 30 min.
The number of missed GA doses in the preceding
14 days and eventual GA discontinuation, whichever
was applicable, were recorded by patients. The comple-
tion of the questionnaire about missed GA doses (adher-
ence) and treatment (dis) continuation (persistence)
took less than 5 min.
Assessment schedule
The MSQoL-54 and MSSES questionnaires were com-
pleted at baseline. Adherence and persistence were
assessed at six predefined and six random time points,
the latter being also unknown to neurologists and MS-
nurses; thus, adherence and persistence were assessed at
4, 10, 12, 16, 20, 26, 32, 34, 38, 44, 48 and 52 weeks.
Statistical analyses
In a previous CAIR study report on the relationship be-
tween persistence and adherence, and the quantity of
care received from multiple disciplines, we found that
95% injected doses was the preferred cut-off point for
adherence. For, the application in persistent patients of
15, 10, 5 and 1% missed doses as cut-off points resulted
in 85, 90, 95 and 99% adherence rates in 99.19, 92.74
84.68 and 47.58% of the patients, respectively; to
maximize our chances to find statistically significant and
clinically relevant differences between adherent and
non-adherent patients we chose 95% adherence as the
cut-off point for non-adherence.
The mean, standard deviation (SD), minimum and
maximum values of the baseline MSQoL-54 Physical,
MSQoL-54 Mental, MSSES Function and MSSES
Control scores were calculated in non-persistent, persist-
ent, persistent non-adherent, and persistent adherent pa-
tients. Differences between non-persistent and persistent
patients, and between persistent non-adherent and per-
sistent adherent patients were tested by means of
Student’s t-test using 0.05 as level of significance.
To assess the extent to which persistence and adher-
ence could be explained by the MSQoL-54 Physical,
MSQoL-54 Mental, MSSES Function and MSSES Con-
trol scores at baseline, we performed a stepwise logistic
regression analysis with forward selection using one or
more of the variables. The order of entering the variables
into the model was determined by the P values of the
correlation with the outcome variable.
Results
Patients, persistence and adherence
Two-hundred-and-three patients were included in the
study, three of which did not complete a single question-
naire [24]. Of the resulting 200 analyzable patients, the
female-to-male ratio was 3.65:1, the mean age 39.7 years
(SD 9.8, minimum 19, maximum 62), and the mean dis-
ease duration (N = 107) 4.5 years (SD 5.0, minimum 0,
maximum 18) [24]. One-hundred-and-twenty-four (62%)
patients were treatment persistent as they continued GA
injections throughout the 12-month study period. In the
persistent group 105 (84.7%) patients were 95% adher-
ent. Treatment persistence was not related to sex (Χ2 =
0.89, P = 0.35) nor to age (T-test = −0.52, P = 0.60), nei-
ther was treatment adherence related to sex (Χ2 = 0.04,
P = 0.84) or to age (T-test = −0.50, P = 0.60).
MSQoL-54 and MSSES scores
The mean, SD, minimum and maximum values of the
MSQoL-54 Physical and Mental scores at baseline in
non-persistent, persistent, persistent non-adherent, and
persistent adherent patients are presented in Table 1.
The persistent group had higher MSQoL-54 Physical
scores than the non-persistent group (T-test = −3.34, P =
0.001), whereas between the non-adherent and adherent
persistent patient groups the MSQoL-54 Physical
scores did not differ (T-test = −0.73, P = 0.46). Simi-
larly, the MSQoL-54 Mental scores were higher in
persistent than in non-persistent patients (T-test =
−2.96, P = 0.003), but there was no difference between
persistent non-adherent and persistent adherent pa-
tients (T-test = −0.62, P = 0.54).
The mean, SD, minimum and maximum values of the
MSSES Function and Control scores at baseline in non-
persistent, persistent, persistent non-adherent, and
persistent adherent patients are presented in Table 2.
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The persistent group had higher MSSES Control
scores than the non-persistent group (T-test = −2.89,
P = 0.0042). Between the persistent non-adherent and
persistent adherent groups the MSSES Control scores
did not differ (T-test = 0.23, P = 0.82). Likewise, the
persistent group had higher MSSES Function scores
than the non-persistent group (T-test = −2.65, P =
0.0087), whereas the MSSES Function scores did not
differ between persistent non-adherent and persistent
adherent patient groups (T-test = −1.12, P = 0.26).
Logistic regression analyses
Regarding treatment persistence, at the first step the
MSQoL-54 Physical score entered the model (P = 0.001)
(MSSES Control P = 0.0031, MSQoL-54 Mental P =
0.0089, MSSES Function P = 0.0134). At the second step
the MSSES Control score was entered (P = 0.2629)
(MSQoL-54 Mental P = 0.5777, MSSES Function P =
0.5395). Then, based on the predicted scores resulting
from the logistic regression model, we classified individual
patients into quartiles and calculated the percentage of
non-persistent patients per quartile. The overall percent-
age of non-persistence in the group (N = 189) was 37%
(see above). Whereas the percentage of non-persistent pa-
tients in the highest quartile was 23%, in the lowest quar-
tile it was 53%, viz. 2.27 times higher (Table 3).
The point estimate of the MSQoL-54 Physical effect
was 1.022, and the point estimate of the MSSES Control
effect was 1.011. In other words, one point increase in
the MSQoL-54 Physical score increases the predicted
score by 2.2%, and ten points increase in the MSSES
control score increases the predicted score by 1.1%.
With respect to adherence, not a single score entered
the model (MSSES function P = 0.2340, MSQoL-54
Physical P = 0.4607, MSQoL-54 Mental P = 0.7891,
MSSES Control P = 0.8207).
Discussion
In a prospective 12-month study in RRMS patients starting
treatment with GA 20 mg sc daily we found, first, that
treatment persistence – but not adherence - was positively
associated with HRQoL and self-efficacy at baseline, and,
second, that a predictive model based on these two mea-
sures might differentiate between patients with a low risk
(about 23%) vs. those with a high risk (about 53%) of treat-
ment discontinuation within 12 months.
In the treatment of chronic disorders patient-related
factors are crucial to persistence and adherence [7].
HRQoL is a multi-dimensional concept that covers the
impact disease has on the patient’s physical, mental,
emotional and social well-being. Since HRQoL is an
overall measure from a patient’s perspective, we hypoth-
esized that in MS patients pre-treatment HRQoL might
relate to persistence of and adherence to DMD treat-
ment. It was found that physical HRQoL seemed to
predict 12-month persistence. To understand this
Table 1 MSQoL-54 Physical and Mental scores in non-persistent, persistent, persistent non-adherent, and persistent adherent
patients at baseline
MSQoL-54 Physical
Non-persistent (n = 70) Persistent (n = 119) Persistent non-adherent (n = 18) Persistent adherent (n = 101)
Mean (SD)
(min.-max.)
49.5 (17.6)*
(13.0-91.5)
58.1 (16.9)*
(21.3-94.8)
55.5 (15.2)
(29.6-79.4)
58.6 (17.2)
(21.3-94.8)
MSQoL-54 Mental
Non-persistent (n = 74) Persistent (n = 123) Persistent non-adherent (n = 19) Persistent adherent (n = 104)
Mean (SD)
(min.-max.)
55.9 (20.4)#
(21.2-94.4)
63.8 (16.8)#
(19.8-90.6)
61.7 (14.9)
(33.5-83.4)
64.2 (17.2)
(19.8-90.6)
MSQoL-54, Multiple Sclerosis Quality of Life-54, min. minimum; max. maximum
*P = 0.001; #P = 0.003
Table 2 MSSES Function and Control scores in non-persistent, persistent, persistent non-adherent, and persistent adherent patients
at baseline
MSSES Function
Non-persistent (n = 58) Persistent (n = 131) Persistent non-adherent (n = 19) Persistent adherent (n = 112)
Mean (SD) (min.-max.) 689 (173)* (280–900) 752 (156)* (90–900) 715 (182) (240–900) 758 (151) (90–900)
MSSES Control
Non-persistent (n = 58) Persistent (n = 131) Persistent and non-adherent (n = 19) Persistent and adherent (n = 112)
Mean (SD) (min.-max.) 491 (192)# (130–900) 568 (178)# (90–900) 560 (140) (210–780) 570 (185) (90–900)
MSSES Multiple Sclerosis Self-Efficacy Scale, min. minimum, max., maximum
*p = 0.0087, #p = 0.0042
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relationship it is of note that in MS patients the discon-
tinuation of DMD treatment has been shown to be signifi-
cantly influenced by the disability level [27]. In fact, RRMS
patients with high disease activity and high disability are
likely to benefit less from first-line DMD treatments, and
may therefore be at a higher risk of early discontinuation.
It has also been known that in MS patients physical
HRQoL correlates with the severity of the disease, e.g. as
measured by the physician-reported Expanded Disability
Status Scale and the relapse rate [9, 28]. Thus, there is a
link to be conceived between pre-treatment low physical
HRQoL and early treatment discontinuation. If this rela-
tionship is substantial, then it would also apply to drug
treatments of other chronic disorders. Actually, in a large
naturalistic study in patients with schizophrenia the 12-
month treatment completion with olanzapine was related
to a better HRQoL at baseline [29].
In our study the adherence to the dosing schedule was
not related to pre-treatment HRQoL. This seems to con-
trast with an international cross-sectional study in over
1900 RRMS patients, finding that adherent patients had a
better quality of life - also with respect to physical well-
being and symptoms - than non-adherent patients [27]; in
addition, women were more likely than men to adhere to
treatment [27]. It has also been demonstrated that patients
with low disability – and thus a conceivably higher HRQoL
- do miss less doses [30]. The fact that our findings are not
in line with these reports may result from the smaller sam-
ple size of our study, our definition of non-adherence, or -
more likely - to us relating adherence to the pre-treatment
HRQoL. As we reported previously, HRQoL may increase
substantially within 3 months after start of GA treatment
and remain so for at least 24 months; so, it may well be that
the increase in HRQoL after the start of treatment explains
for the relationship between on-treatment HRQoL and ad-
herence, as better adherence will expectedly result in a
higher increase in HRQoL [31, 32].
Our data suggest that adherence is to a certain degree
influenced by other factors than those affecting persist-
ence, the latter being lack of effectiveness and side
effects. A study in hypertensive patients indicated that
events interfering with daily routine had a significant im-
pact on adherence, and that adherence appears to be a
patterned behaviour established through the creation of
a routine and a reminder system for taking the medica-
tion [33]. Recently, it has been found that in GA-treated
MS patients the most common reason for missing injec-
tions is that they simply forget to administer the medica-
tion [12], other factors being not feeling like taking or
being tired of taking the injections, skin reactions, pain
at injection sites, injection-related anxiety and the ab-
sence of someone to help administer the medication
[12]. Similarly, non-adherence among kidney transplant
patients on immunosuppressant therapy, where admit-
ted, was unintentional [34] and due to forgetfulness,
interference with lifestyle, change in routine, and impact
of side effects [34]. So, it is likely that in patients with
chronic disorders non-adherence primarily relates to
cognitive, practical and treatment-related factors, which
are in part different from those affecting persistence and
are, except from cognitive factors, not reflected by pre-
treatment HRQoL.
Another finding in our study was that control self-
efficacy seemed to predict 12-month persistence.
Control self-efficacy reflects the individual’s sense of
confidence that he/she can control disease symptoms,
reactions to disease-related limitations, and the effect of
the disease on life activities [26]. Thus, the ‘control self-
efficacy’ concept links the patient’s self-confidence to
his/her disease state. Already in 2001 Fraser et al., meas-
uring self-efficacy via the MSSES in a retrospective sur-
vey in 341 GA-treated RRMS patients, found that those
who had not discontinued treatment in the first year,
had a higher level of control self-efficacy (mean 595, SD
184) than the patients who had discontinued (mean 532,
SD 182) [18]; in contrast to our study, the function self-
efficacy score did not differ between persistent en non-
persistent patients (mean 742, SD 166 vs. mean 712, SD
167) [18]. In a prospective study Zwibel et al. found that
greater function self-efficacy predicted 12-week GA
persistence in treatment-naive patients, but not in
treatment-experienced patients [20].
Cognitive problems were not an exclusion criterion for
study participation, in spite of their frequent occurrence
in MS [35]. This choice was motivated by the following
considerations. First, given the real-life nature of the
study, exclusion of cognitively impaired patients would
have interfered with the generalisability of the study con-
clusions. Second, it has been shown that cognitive im-
pairment in MS does not affect reliability and validity of
self-report health measures, including HRQoL [36].
Greater use of screening and assessment tools is
needed to identify and target the patients who are at the
greatest risk for not taking medication as agreed [37].
And although we know about common features of
Table 3 Percentage and number of persistent vs. non-persistent
patients per quartile of predicted scores based on baseline MSQoL-
54 Physical and MSSES Control scores
Quartile Percentage non-persistent
patients
Percentage persistent
patients
N total
4 23.40 (n = 11) 76.60 (n = 36) 47
3 25.00 (n = 12) 75.00 (n = 36) 48
2 46.81 (n = 22) 53.19 (n = 25) 47
1 53.19 (n = 25) 46.81 (n = 22) 47
Total 37.04 (n = 70) 62.96 (n = 119) 189
MSQoL-54 Multiple Sclerosis Quality of Life-54, MSSES Multiple Sclerosis Self-Efficacy
Scale; Χ2 = 13.91, p= 0.0030
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adherence or persistence improving programs, it is difficult
to determine the best possible combination of such features
for any given patient [37]. Zwibel et al. suggested that find-
ings in GA-treated RRMS patients on the relationship be-
tween HRQoL/self-efficacy and persistence may justify
interventions to improve persistence [20]. Based on our ob-
servations, we propose a prognostic and interventional
work-up scheme to identify those RRMS patients starting a
first-line injectable DMD treatment who are at high risk
(>50%) of early discontinuation, and to guide in these pa-
tients the use of persistence improving measures (Table 4).
In Step 1 physical HRQoL and control self-efficacy are
assessed and a predictive score is calculated to identify high
risk patients. Once the right patients are identified, inter-
ventions can be tailored to individual patients [37]. In our
proposal step 2A focuses on the screening of symptoms
that are known to be associated with a lower HRQoL in
MS: depression, anxiety, fatigue and bladder symptoms; it
had already been recognized that treatment guidelines for
chronic conditions should recommend screening for de-
pression, as this can be an indicator of poor persistence and
adherence [37, 38]. Then, to improve the chances of persist-
ence in individual patients, we propose interventional mea-
sures to be taken based on abnormal outcomes of the
additional screenings. In step 2B we suggest to re-assess
prognostic factors in order to detect patients with an ex-
pectedly unfavourable disease course, in whom a first-line
DMD may be insufficiently effective. Interestingly, a recent
study, showing that in MS patients depression, anxiety, and
fatigue are associated with a decreased HRQoL, is in line
with our approach [39]. It is of note that the idea to address
multiple HRQoL-related factors presupposes, first, that
these factors relate causally to persistence and, second, that
positively influencing these factors will improve persistence.
The concept of addressing multiple HRQoL-related factors
simultaneously is supported by a recent review, which
states that multi-component interventions showed the
strongest evidence for promoting adherence in patients
with immune-mediated inflammatory disorders [40].
Importantly, the approach that we propose does not de-
pend on doctor- or nurse-based scores, and therefore its
interference with daily neurological practice will be limited.
Steps 1 and 2a are based on patient-reported outcomes,
preferentially obtained via web-based questionnaires that
are completed at home [41]; this contrasts with e.g. the
time-consuming Expanded Disability Status Scale score.
Ideally, patients complete the HRQoL and self-efficacy
questionnaires prior to the outpatient consultation; the pre-
dictive score is generated automatically via an algorithm;
online presented to the patient, neurologist and nurse
[41, 42]; and, if indicated, questionnaires for additional as-
sessments are made available. In our opinion, the use of
web-based patient-reported outcomes and their integration
in the daily care process, makes persistence-promoting
solutions feasible at the individual and practice level [43].
As to the limitations of our study, it may be argued, first,
that the predictive score is less applicable to the INFb
group of injectable DMDs, as these may negatively affect
fatigue and mood, both major constituents of HRQoL.
However, as it is the baseline value of HRQoL that contrib-
utes to the prediction of persistence, and not the HRQoL
during treatment, such an effect may be questioned. More-
over, in a previous study in IM INFb-treated patients we
found that lower physical or mental HRQoL at baseline
was indeed associated with treatment discontinuation
within 24 months [13]. Second, the predictive score is based
on a single data set that was obtained in patients treated
with the same injectable DMD. Therefore, the predictive
value of the score should be confirmed in prospective stud-
ies and in patients treated with other DMDs.
Conclusions
Findings in this prospective web-based patient-centred
study in RRMS patients starting treatment with GA 20 mg
sc daily suggest that pre-treatment physical HRQoL and
control self-efficacy may identify patients with a high risk of
early injectable DMD treatment discontinuation. Based on
these results we propose a step-wise approach to identify
high-risk patients and to efficiently choose individualized
persistence-promoting measures in daily practice. Future
studies are needed to validate the predictive model and to
assess the (cost-) effectiveness of the proposed follow-up.
Table 4 Step-wise approach to identify RRMS patients with a high risk (>50%) of early injectable DMD treatment discontinuation
and to guide persistence improving measures
To be assessed Tool Outcome Action
Step 1 Physical HRQoL
Control self-efficacy
MQoL-54
MSSES
Predictive score If score in lowest quartile
(>50% discontinuation risk)→ 2A & 2B
Step 2A Depression & anxiety
Fatigue
Bladder
HADS
MFIS
Actionable
Diagnostic scores If score(s) abnormal→ further diagnosis
and therapy
If MSSES score(s) low→ therapy?
Step 2B Prognosis 1) Clinical
2) MRI
3) CSF
Prognostic indicators If prognosis unfavourable > consider 2nd
line DMD
MS multiple sclerosis, DMD disease modifying drug, HRQoL health-related quality of life, MSQoL-54 Multiple Sclerosis Quality of Life-54, MSSES Multiple Sclerosis
Self-Efficacy Scale, HADS Hospital Anxiety and Depression Scale, MFIS Modified Fatigue Impact Scale, MRI magnetic resonance imaging, CSF cerebrospinal fluid
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